This viewpoint aims to address the implications of an executive order on psychedelic drug development and clinical integration.
Discusses issues surrounding the ethical integration of psychedelic therapies.
Outlines potential frameworks for the development and approval of psychedelic drugs.
Analyzes evidence-based approaches for clinical care involving psychedelics.
Highlights the need for ethical considerations in the application of psychedelic therapies.
Emphasizes the importance of evidence-based practices in integrating these therapies into clinical settings.
Resumen
This Viewpoint discusses the executive order supporting the development and approval of psychedelic drugs and outlines issues surrounding their ethical and evidence-based integration into clinical care.